Tang Chunlan, Yang Heping, Zhou Xiangdong
Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Zhongguo Fei Ai Za Zhi. 2011 Dec;14(12):960-4. doi: 10.3779/j.issn.1009-3419.2011.12.11.
Lung cancer is the most common cause of death from cancer worldwide per year. Platinum-based combination chemotherapy is a main treatment of lung cancer. Cisplatin is adopted widely and used effectively in the first-line chemotherapy. Unfortunately, development of cisplatin resistance is a major obstacle to the success of lung caner. Cisplatin is a cell-cycle-non-specific cytotoxic drugs and its main target is DNA. Thus, defective DNA damage repair is one of the main mechanisms of cisplatin resistance. In this review, we will focus on the defective DNA damage repair in cisplatin resistance of lung cancer including nucleotide excision repair, DNA mismatch repair, DNA double-strand break repair and translesion synthesis.
肺癌是全球每年因癌症死亡的最常见原因。铂类联合化疗是肺癌的主要治疗方法。顺铂在一线化疗中被广泛采用且效果良好。不幸的是,顺铂耐药的产生是肺癌治疗成功的主要障碍。顺铂是一种细胞周期非特异性细胞毒性药物,其主要靶点是DNA。因此,DNA损伤修复缺陷是顺铂耐药的主要机制之一。在这篇综述中,我们将聚焦于肺癌顺铂耐药中DNA损伤修复缺陷,包括核苷酸切除修复、DNA错配修复、DNA双链断裂修复和跨损伤合成。